Genmab — November 2019
-
Dara + ATRA disappointing: Overall, this approach resulted in a modest prolongation of PFS. Patients with primary DARA-refractory disease did not benefit from the addition of ATRA. However, in patients with ≥PR on DARA monotherapy prior to progression, addition of ATRA and re-intensification of DARA was of marked clinical benefit with an additional 7.8 months of disease control. https://ash.confex.com/ash/2019/webprogram/Paper123383.html
-
Men deres patent har ikke så lang levetid mere.
https://www.biopharmadive.com/news/celgene-revlimid-patent-challenge-dr-reddys-ptab/548172/ -
-
God morgen.
-
Merck and Pfizer's PD-L1 Bavencia ( avelumab ) fejler et PH III forsøg i gastric cancer. https://m.firstwordpharma.com/merck-kgaa-pfizer-say-late-stage-study-bavencio-gastric-cancer-misses-primary-endpoints
-
voldsom omsætning
-
ja køberne er vedholdende her til morgen
-
knapt 4000 handlede aktier i minuttet, for de første 12 minutter, det er sjældent det sker
-
84 millioner omsat på tyve minutter. Det er en sjat.
-
99 mio på 30 minutter.
-
Der er nogle opgørelser over (jeg har ikke lige styr på hvor), hvilket GAK shorter-fondene sidder med. Er der nogen som ligger inde med dette overblik og kan dele. Kunne være interessant at vide hvor mange shortere som brænder inde...
-
Hanken knækkede af. Hvem kommer med superlimen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind